Abstract
The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current "best practice" in Switzerland.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Biological Products / therapeutic use*
-
Humans
-
Methotrexate / therapeutic use
-
Remission Induction
-
Switzerland
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antirheumatic Agents
-
Biological Products
-
Tumor Necrosis Factor-alpha
-
Methotrexate